Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real World Study Evaluating the Outcomes of Ixazomib, Lenalidomide and Dexamethasone (IRD) in Patients with Relapsed and Refractory Multiple Myeloma from a Compassionate Named Patient Program

Trial Profile

A Real World Study Evaluating the Outcomes of Ixazomib, Lenalidomide and Dexamethasone (IRD) in Patients with Relapsed and Refractory Multiple Myeloma from a Compassionate Named Patient Program

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 29 Jul 2018 New trial record
    • 17 Jun 2018 Results (n=118) presented at the 23rd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top